Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Synopsis
2.2. Discovery and Technical Validation Cohort
2.3. Biological Validation Cohort
2.4. Urine-Based Clinical Cohort
2.5. Discovery—Laboratory Methods
2.6. Technical Validation—Laboratory Methods
2.7. Biological Validation—Laboratory Methods
2.8. TELQAS Assays
2.9. Urine Collection and Processing
2.10. Statistical Analysis—Discovery and Technical Validation
2.11. Statistical Analysis—Biological Validation and Urine Testing
3. Results
3.1. PCa MDM Discovery and Technical Validation
3.2. Biological Validation of Candidate PCa MDMs
3.3. Testing Candidate PCa MDMs in Urine of Men with and without PCa
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef]
- Hu, J.C.; Nguyen, P.; Mao, J.; Halpern, J.; Shoag, J.; Wright, J.D.; Sedrakyan, A. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. JAMA Oncol. 2017, 3, 705–707. [Google Scholar] [CrossRef] [PubMed]
- Burgess, L.; Aldrighetti, C.M.; Ghosh, A.; Niemierko, A.; Chino, F.; Huynh, M.J.; Efstathiou, J.A.; Kamran, S.C. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening with Prostate Cancer-Specific Mortality. JAMA Netw. Open 2022, 5, e2211869. [Google Scholar] [CrossRef]
- Carroll, P.R.; Parsons, J.K.; Andriole, G.; Bahnson, R.R.; Castle, E.P.; Catalona, W.J.; Dahl, D.M.; Davis, J.W.; Epstein, J.I.; Etzioni, R.B.; et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J. Natl. Compr. Canc. Netw. 2016, 14, 509–519. [Google Scholar] [CrossRef] [PubMed]
- Wei, J.T.; Barocas, D.; Carlsson, S.; Coakley, F.; Eggener, S.; Etzioni, R.; Fine, S.W.; Han, M.; Kim, S.K.; Kirkby, E.; et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J. Urol. 2023, 210, 46–53. [Google Scholar] [CrossRef]
- Wei, J.T.; Barocas, D.; Carlsson, S.; Coakley, F.; Eggener, S.; Etzioni, R.; Fine, S.W.; Han, M.; Kim, S.K.; Kirkby, E.; et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J. Urol. 2023, 210, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [Google Scholar] [CrossRef]
- Ehrlich, M. DNA hypermethylation in disease: Mechanisms and clinical relevance. Epigenetics 2019, 14, 1141–1163. [Google Scholar] [CrossRef] [PubMed]
- Bock, C.; Tomazou, E.M.; Brinkman, A.B.; Müller, F.; Simmer, F.; Gu, H.; Jäger, N.; Gnirke, A.; Stunnenberg, H.G.; Meissner, A. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol. 2010, 28, 1106–1114. [Google Scholar] [CrossRef]
- Zou, H.; Allawi, H.; Cao, X.; Domanico, M.; Harrington, J.; Taylor, W.R.; Yab, T.; Ahlquist, D.A.; Lidgard, G.Z. Quantification of methylated markers with a multiplex methylation-specific technology. Clin. Chem. 2012, 58, 375–383. [Google Scholar] [CrossRef]
- Kisiel, J.B.; Dukek, B.A.; VSR Kanipakam, R.; Ghoz, H.M.; Yab, T.C.; Berger, C.K.; Taylor, W.R.; Foote, P.H.; Giama, N.H.; Onyirioha, K.; et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology 2019, 69, 1180–1192. [Google Scholar] [CrossRef]
- Gu, H.; Smith, Z.D.; Bock, C.; Boyle, P.; Gnirke, A.; Meissner, A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 2011, 6, 468–481. [Google Scholar] [CrossRef]
- Li, L.C.; Dahiya, R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002, 18, 1427–1431. [Google Scholar] [CrossRef]
- Sun, Z.; Baheti, S.; Middha, S.; Kanwar, R.; Zhang, Y.; Li, X.; Beutler, A.S.; Klee, E.; Asmann, Y.W.; Thompson, E.A.; et al. SAAP-RRBS: Streamlined analysis and annotation pipeline for reduced representation bisulfite sequencing. Bioinformatics 2012, 28, 2180–2181. [Google Scholar] [CrossRef]
- Qin, Y.; Wu, C.W.; Taylor, W.R.; Sawas, T.; Burger, K.N.; Mahoney, D.W.; Sun, Z.; Yab, T.C.; Lidgard, G.P.; Allawi, H.T.; et al. Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. Clin. Cancer Res. 2019, 25, 7396–7404. [Google Scholar] [CrossRef] [PubMed]
- Anderson, B.W.; Suh, Y.S.; Choi, B.; Lee, H.J.; Yab, T.C.; Taylor, W.R.; Dukek, B.A.; Berger, C.K.; Cao, X.; Foote, P.H.; et al. Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. Clin. Cancer Res. 2018, 24, 5724–5734. [Google Scholar] [CrossRef] [PubMed]
- Xie, H.; Mahoney, D.W.; Foote, P.H.; Burger, K.N.; Doering, K.A.; Taylor, W.R.; Then, S.S.; Cao, X.; McGlinch, M.; Berger, C.K.; et al. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clin. Cancer Res. 2020, 27, 141–149. [Google Scholar] [CrossRef]
- Marinelli, L.M.; Kisiel, J.B.; Slettedahl, S.W.; Mahoney, D.W.; Lemens, M.A.; Shridhar, V.; Taylor, W.R.; Staub, J.K.; Cao, X.; Foote, P.H.; et al. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol. Oncol. 2022, 165, 568–576. [Google Scholar] [CrossRef]
- Blyth, C.R.; Still, H.A. Binomial confidence intervals. J. Am. Stat. Assoc. 1983, 78, 108–116. [Google Scholar] [CrossRef]
- Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224ra224. [Google Scholar] [CrossRef]
- Vickers, A.; Cronin, A.; Roobol, M.; Savage, C.; Peltola, M.; Pettersson, K.; Scardino, P.T.; Schröder, F.; Lilja, H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J. Clin. Oncol. 2010, 28, 2493–2498. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Xu, D.; Ruan, M.; Li, H.; Lin, G.; Song, G. A prospective study of the prostate health index density and multiparametric magnetic resonance imaging in diagnosing clinically significant prostate cancer. Investig. Clin. Urol. 2023, 64, 363–372. [Google Scholar] [CrossRef] [PubMed]
- McKiernan, J.; Donovan, M.J.; O’Neill, V.; Bentink, S.; Noerholm, M.; Belzer, S.; Skog, J.; Kattan, M.W.; Partin, A.; Andriole, G.; et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016, 2, 882–889. [Google Scholar] [CrossRef] [PubMed]
- Van Neste, L.; Partin, A.W.; Stewart, G.D.; Epstein, J.I.; Harrison, D.J.; Van Criekinge, W. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate 2016, 76, 1078–1087. [Google Scholar] [CrossRef]
- Borque-Fernando, Á.; Rubio-Briones, J.; Esteban, L.M.; Dong, Y.; Calatrava, A.; Gómez-Ferrer, Á.; Gómez-Gómez, E.; Gil Fabra, J.M.; Rodríguez-García, N.; López González, P.Á.; et al. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer Prostatic Dis. 2019, 22, 84–90. [Google Scholar] [CrossRef] [PubMed]
- Margolis, E.; Brown, G.; Partin, A.; Carter, B.; McKiernan, J.; Tutrone, R.; Torkler, P.; Fischer, C.; Tadigotla, V.; Noerholm, M.; et al. Predicting high-grade prostate cancer at initial biopsy: Clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022, 25, 296–301. [Google Scholar] [CrossRef] [PubMed]
- Schrag, D.; Beer, T.M.; McDonnell, C.H.L.; Dilaveri, C.A.; Reid, R.; Marinac, C.R.; Chung, K.C.; Lopatin, M.; Fung, E.T.; Klein, E.A. Blood-based tests for multicancer early detection (PATHFINDER): A prospective cohort study. Lancet. 2023, 402, 1251–1260. [Google Scholar] [CrossRef]
Case (N = 24) | Control (N = 24) | |
---|---|---|
Age (years) | ||
Median (Q1, Q3) | 65.4 (60.6, 71.2) | 70.4 (66.9, 72.3) |
Race | ||
Caucasian | 22 (91.7%) | 23 (95.8%) |
Unknown | 2 (8.3%) | 1 (4.2%) |
Tobacco Use | ||
Yes, but not in last 3 months | 14 (58.3%) | 14 (58.3%) |
Currently or in last three months | 1 (4.2%) | 1 (4.2%) |
Never | 9 (37.5%) | 9 (37.5%) |
Most Recent PSA Normal | ||
N-Miss | - | 8 |
Yes | - | 16 (100.0%) |
Most Recent PSA Value | ||
N-Miss | 3 | - |
Median (Q1, Q3) | 6.4 (4.9, 9.0) | - |
History of Prostatitis | 3 (12.5%) | - |
Family History of Prostate Cancer | 4 (16.7%) | - |
Nodules Present | ||
No | 15 (62.5%) | - |
Yes | 2 (8.3%) | - |
Unknown | 7 (29.2%) | - |
Prostatic atrophy | ||
No | 21 (87.5%) | - |
Yes | 1 (4.2%) | - |
Unknown | 2 (8.3%) | - |
Prostatic fibrosis | ||
No | 22 (91.7%) | - |
Unknown | 2 (8.3%) | - |
Prostatitis | ||
None | 22 (91.7%) | - |
Unknown | 2 (8.3%) | - |
Gleason Score | ||
Gleason 6 | 7 (29.2%) | - |
Gleason 7 | 12 (50.0%) | - |
Gleason 8 | 1(4.2%) | - |
Gleason 9 | 4 (16.7%) | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shah, P.; Taylor, W.R.; Negaard, B.J.; Gochanour, B.R.; Mahoney, D.W.; Then, S.S.; Devens, M.E.; Foote, P.H.; Doering, K.A.; Burger, K.N.; et al. Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer. Life 2024, 14, 1024. https://doi.org/10.3390/life14081024
Shah P, Taylor WR, Negaard BJ, Gochanour BR, Mahoney DW, Then SS, Devens ME, Foote PH, Doering KA, Burger KN, et al. Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer. Life. 2024; 14(8):1024. https://doi.org/10.3390/life14081024
Chicago/Turabian StyleShah, Paras, William R. Taylor, Brianna J. Negaard, Benjamin R. Gochanour, Douglas W. Mahoney, Sara S. Then, Mary E. Devens, Patrick H. Foote, Karen A. Doering, Kelli N. Burger, and et al. 2024. "Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer" Life 14, no. 8: 1024. https://doi.org/10.3390/life14081024